A clinical Trial to Study the Effects of Hydroxychloroquine, Ciclesonide and Ivermectin in treatment of moderate COVID-19 illness

INTERVENTION: Intervention1: Hydroxychloroquine: 400 mg bid Day1 followed by 200 mg bid on Days 2 to 7 Intervention2: Ciclesonide: 200 mcg bid for 7 days Intervention3: Ivermectin: 12 mg OD for 7 days Control Intervention1: Standard of Care: Supportive management as per national guidelines CONDITION: Health Condition 1: B972‐ Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B338‐ Other specified viral diseases PRIMARY OUTCOME: Proportion of patients having virologic cure on Day 6 in each of the groupsTimepoint: Day 6 of treatment initiation SECONDARY OUTCOME: o Proportion of patients having resolution of symptoms/signs on Day 7 and Day 14, in each of the groups ; o The individual proportion of the aforementioned rescue criteria in each of the groups. ; o Side‐effects noted in each of the group ; Timepoint: Day 7 and Day 14 INCLUSION CRITERIA: â?¢ Adult patients (â?Â¥18years) suffering from Covid‐19. A positive throat swab (by real time PCR) obtained from a patient suspected to be Covid‐19 or from a contact (or HCW) of Covid‐19 patient will be considered to be a Covid‐19 case. â?¢ Presence of moderate Covid‐19 disease (10) as defined by presence of pneumonia (clinical and radiological signs) with respiratory rate between 15 to 30/minute and/or SpO2 90%‐94% on room air.